PAREXEL has introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals. PAREXEL Biotech builds on the company’s clinical, regulatory, commercial and technology services with enhanced strategic consulting and asset development capabilities, offering a new Biotech-focused team and organizational structure for customers. Led by James Anthony, Global Head of Biotech, and Graciela Racaro, Global Head of Biotech Operations, the division will help emerging companies minimize complexity, reduce costs, and accelerate timelines. 
 
“Today’s emerging biotech companies have an increasingly critical role in identifying and developing new medicines that truly serve as the innovative arm of the industry,” said James Anthony. “However, these companies face significant pressures and challenges in terms of timelines, resources and funding to succeed.”
 
Graciela Racaro added, “We look forward to combining PAREXEL’s expertise and global infrastructure with an agile and efficient delivery model that is aligned to this specific segment, enabling emerging biotech companies to focus on their core capabilities and reach their strategic goals.”
 
PAREXEL Biotech will take a consultative approach to help companies achieve their objectives throughout discovery, proof of concept, development, registration and commercialization, with services that include: global regulatory and strategy consulting, China advisory services, quantitative clinical development and genomic medicine services, patient recruitment services, trial execution services, and Real World Evidence programs.